One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Cross-trial comparisons in reviews: proceed with caution
Keith M. Sullivan & Lynette Keyes-Elstein
doi : 10.1038/s41584-020-0492-3
page 663–664(2020)
HCQ use not protective against SARS-CoV-2
Sarah Onuora
doi : 10.1038/s41584-020-00529-3
page 666(2020)
At-risk individuals willing to start interventions
Sarah Onuora
doi : 10.1038/s41584-020-00530-w
page 666(2020)
Multimorbidity worse in patients with RA
Sarah Onuora
doi : 10.1038/s41584-020-00531-9
page 666(2020)
Depression linked to seronegative RA risk
Sarah Onuora
doi : 10.1038/s41584-020-00532-8
page 666(2020)
IRF5 inhibitor shows promise in mouse models of SLE
Jessica McHugh
doi : 10.1038/s41584-020-00525-7
page 667 (2020
JAK1 inhibitor superior to abatacept in head-to-head RA trial
Sarah Onuora
doi : 10.1038/s41584-020-00535-5
page 667 (2020)
SUMOylation links metabolic and aggressive phenotype of RA FLS
Jessica McHugh
doi : 10.1038/s41584-020-00526-6
page 668 (2020)
Abnormal gut transit linked to gastrointestinal symptoms in SSc
Sarah Onuora
doi : 10.1038/s41584-020-00537-3
page 668 (2020)
The road to equity for women in academic rheumatology
Shereen N. Mahmood & Irene Blanco
doi : 10.1038/s41584-020-00517-7
page 669–670 (2020)
Revisiting the cardiovascular risk of hydroxychloroquine in RA
Yves-Marie Pers & Guillaume Padern
doi : 10.1038/s41584-020-00521-x
page 671–672 (2020)
Emerging pharmaceutical therapies for osteoarthritis
Augustin Latourte, Margreet Kloppenburg & Pascal Richette
doi : 10.1038/s41584-020-00518-6
page 673–688 (2020)
The prevalence of osteoarthritis (OA) and the burden associated with the disease are steadily increasing worldwide, representing a major public health challenge for the coming decades.
Immune-mediated necrotizing myopathy: clinical features and pathogenesis
Yves Allenbach, Olivier Benveniste, Werner Stenzel & Olivier Boyer
doi : 10.1038/s41584-020-00515-9
page 689–701 (2020)
Immune-mediated necrotizing myopathy (IMNM) is a group of inflammatory myopathies that was distinguished from polymyositis in 2004.
IgG4-related disease: an update on pathophysiology and implications for clinical care
Cory A. Perugino & John H. Stone
doi : 10.1038/s41584-020-0500-7
page 702–714(2020)
IgG4-related disease (IgG4-RD) has only existed as a unique disease entity since 2003, yet remarkable progress has already been achieved in describing the essential features of the disease.
Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases
Xavier Bossuyt, Ellen De Langhe, Maria Orietta Borghi & Pier Luigi Meroni
doi : 10.1038/s41584-020-00522-w
page 715–726(2020)
Antinuclear antibodies (ANAs) are valuable laboratory markers to screen for and support the diagnosis of various rheumatic diseases (known as ANA-associated rheumatic diseases).
